---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-085479"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:44:55.200311+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Intellia shareholders elect three Class III directors and approve 2025 equity plan

## Summary
- Elected William Chase, Georgia Keresty, and John M. Leonard as Class III directors for three-year terms ending 2028.
- Approved the 2025 Equity Incentive Plan: 50.8M for, 13.6M against, 93.8K abstentions.
- Ratified Deloitte & Touche as independent auditor for FY2025: 82.1M for, 497.8K against.
- Advisory say-on-pay vote passed (45.8M for, 18.6M against); future votes will be held annually.
- Broker non-votes were 18.3M on director elections, equity plan, and say-on-pay.

## SEC filing metadata
- accession: 0000950170-25-085479
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017025085479/0000950170-25-085479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017025085479/ntla-20250611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-085479
- JSON: https://secwatch.observer/filing/0000950170-25-085479.json
- Plain text: https://secwatch.observer/filing/0000950170-25-085479.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.